VMD VIEMED HEALTHCARE, INC.
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1729149 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.8%
TTM net income YoY14.8%
TTM EPS YoY11.8%
Revenue 3-yr CAGR22.3%
Net income 3-yr CAGR19.3%
Margins
Gross margin57.4%
Operating margin7.8%
Net margin5.0%
FCF margin6.9%
EBITDA margin12.9%
Returns
ROE11.0%
ROA7.6%
ROIC (approx.)11.8%
Asset turnover1.51x
Leverage & solvency
Liabilities / assets26.8%
Debt / equity0.03x
Current ratio1.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.45x
Accruals ratio-18.7%
Payout ratio—
Capex / revenue10.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $270.28M | $224.26M |
| Cost of revenue | $114.82M | $91.05M |
| Gross profit | $155.46M | $133.20M |
| R&D expense | $3.02M | $3.07M |
| SG&A expense | $121.37M | $106.20M |
| Operating income | $22.95M | $17.90M |
| Pretax income | $21.77M | $16.17M |
| Income tax | $6.39M | $4.76M |
| Net income | $14.93M | $11.27M |
| EBITDA | $51.56M | $43.27M |
| EPS (basic) | 0.38 | 0.29 |
| EPS (diluted) | 0.37 | 0.28 |
| Weighted avg. shares (diluted) | 40.82M | 40.81M |
| Balance sheet | ||
| Cash & equivalents | $13.50M | $17.54M |
| Receivables | $25.59M | $24.91M |
| Inventory | $5.05M | $4.32M |
| Current assets | $48.49M | $52.88M |
| PP&E, net | $78.78M | $76.28M |
| Goodwill | $58.94M | $32.99M |
| Intangibles | $1.28M | $848,000 |
| Total assets | $199.15M | $177.07M |
| Current liabilities | $41.06M | $37.33M |
| Short-term debt | $1.09M | $409,000 |
| Long-term debt | $11.29M | $3.59M |
| Total debt | $12.38M | $4.00M |
| Total liabilities | $55.63M | $43.77M |
| Shareholders' equity | $141.54M | $131.39M |
| Net debt | -$1.12M | -$13.54M |
| Shares outstanding | 38.02M | 39.13M |
| Cash flow statement | ||
| Operating cash flow | $51.92M | $39.09M |
| Capital expenditure | $39.98M | $37.77M |
| Free cash flow | $11.93M | $1.32M |
| Investing cash flow | -$50.17M | -$30.70M |
| Financing cash flow | -$5.79M | -$3.69M |
| Depreciation & amortization | $28.61M | $25.37M |
| Stock-based compensation | $9.13M | $6.29M |
| Share buybacks | $13.22M | $0 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.